查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1916222

前列腺特异性膜抗原抑制剂市场按分子类型、癌症分期、治疗线、给药途径、患者年龄层、应用和最终用户划分－2026-2032年全球预测

Prostate-Specific Membrane Antigen Inhibitor Market by Molecule Type, Cancer Stage, Treatment Line, Administration Route, Patient Age Group, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025 年前列腺特异性膜抗原抑制剂市值为 6.8732 亿美元，预计到 2026 年将成长至 7.0467 亿美元，预计到 2032 年将达到 8.7632 亿美元，复合年增长率为 3.53%。

关键市场统计数据
基准年 2025 6.8732亿美元
预计年份：2026年 7.0467亿美元
预测年份 2032 8.7632亿美元
复合年增长率 (%) 3.53%

对现代PSMA抑制剂的研发和应用所涉及的科学原理、临床需求和操作复杂性进行严谨的概述

前列腺特异性膜抗原 (PSMA) 抑制剂已成为前列腺癌诊断影像和标靶治疗交叉领域的关键药物。这些药物利用前列腺癌细胞中 PSMA 的过度表现，实现精准的肿瘤可视化和细胞毒性药物的选择性递送，从而构建了一个整合诊断和治疗目的的统一诊疗一体化框架。 PSMA治疗诊断学的临床应用涵盖了从早期检测到晚期疾病管理的各个阶段，并且该技术对各种成像平台和放射性配体偶联物的适应性，重新激发了临床医生、监管机构和投资者的浓厚兴趣。

放射化学、治疗诊断学、监管清晰度和供应链模式等领域的创新融合如何重塑PSMA抑制剂的竞争地位

近年来，科学创新、监管路径和商业性预期方面的变革性转变共同重塑了PSMA抑制剂的格局。放射化学和偶联技术的进步，使治疗手段从单株抗体扩展到结构紧密的小分子，从而实现了更快的肿瘤渗透和更多样化的给药途径。同时，治疗诊断学模式的成熟，使得诊断影像检查不再是下游步骤，而是病患选择、治疗反应评估和适应性治疗计画不可或缺的一部分，进而影响临床结果和医保报销。

评估贸易政策和关税制度的变化将如何影响放射性药物的采购经济性、供应链韧性和区域製造策略。

调整关税和贸易壁垒的政策决定将对放射性药物的研发、生产和分销的经济效益产生重大影响。对临床同位素、特殊前驱物或放射性药物生产所需设备征收或提高税收，会增加製造商和合约服务提供者的投入成本。这些额外成本会波及整个采购管道，促使企业重新评估筹资策略、将生产集中到低成本地区以及采取同位素供应对冲策略。因此，赞助公司可能会加快对当地放射化学基础设施的投资，或寻求供应协议以实现生产内部化，从而降低跨国关税风险。

全面的細項分析揭示了应用类型、分子类别、疾病阶段、治疗线、护理环境、给药途径和年龄组如何影响产品策略。

细緻的细分框架揭示了临床、商业性和营运方面的优先事项在不同应用、分子类别、疾病状态、治疗方案、最终用户、给药途径和患者群体中的异同之处。从应用角度来看，诊断影像和治疗途径需要不同的能力。诊断影像强调高解析度PET和SPECT的兼容性以及与诊断检查室和影像中心的流程整合，而治疗则需要放射性配体或小分子药物方面的专业知识，以及放射性卤化物和放射性金属偶联能力和治疗后安全性监测。就分子类型而言，单株抗体（包括嵌合体和人源化抗体）具有成熟的蛋白质工程和监管先例，而磷酰胺类和脲类药物等小分子药物则具有生产製程简化和药物动力学特性良好的优势，支持更广泛的给药策略。

区域临床和商业性趋势正在推动PSMA诊断和治疗在美洲、欧洲、中东和非洲以及亚太地区的应用路径各不相同。

区域趋势造就了不同的临床、监管和商业性环境，进而影响PSMA抑制剂计画的开发和部署。在美洲，先进的影像基础设施、许多地区已建立的新型诊断报销机制以及集中的临床卓越中心，使得临床试验的快速招募和治疗性诊断方法的早期应用成为可能。然而，公立和私立医疗系统之间支付方的差异，使得制定客製化的定价和证据产生策略成为必要。在欧洲、中东和非洲地区，监管的多样性以及区域间在获取专业放射性药物生产能力​​方面的差异，往往导致集中式生产模式与新兴的本地化生产模式并存。相关人员必须仔细考虑影响计画实施时间表的各种报销政策和转诊途径。

竞争与合作并存的产业趋势强调配体创新、放射化学规模化生产以及策略联盟，以实现临床优势和供应链安全。

在竞争激烈的市场环境中，企业组织策略凸显了对整合能力的重视，这些能力涵盖药物发现、放射化学放大生产、临床检验和商业物流等各个环节。创新生物技术公司致力于优化配体设计、提高亲和性，并开发能够同时实现影像和治疗结合的小分子结构。传统製药公司则利用其监管方面的专业知识、生产规模和与支付方的良好关係，加速后期研发进程，并与医疗系统和集团采购组织（GPO）协商供应协议。同时，专业的放射性药物生产商和合约研发生产机构（CDMO）正在拓展其同位素处理、自动化合成以及无菌填充包装能力，以满足放射性配体疗法的独特需求。

为经营团队将科学创新、供应链韧性、监管合作和以支付方为中心的证据产生整合到PSMA专案中的实用建议

产业领导者必须采取积极主动的策略，将科学发展与供应链韧性、监管互动以及以支付方为中心的证据产生结合。首先，应优先考虑平台柔软性，并投资于适用于成像和治疗的配体化学和偶联技术。平台的多功能性能够加快新适应症的上市速度，并实现临床试验资源的有效利用。其次，为降低供应侧风险，应透过同位素来源多元化和建立区域性生产伙伴关係关係，减少对单一地区的依赖。近岸外包和合作生产协议能够确保即使在贸易环境动盪的情况下，也能保障临床供应。

我们采用可重复且透明的调查方法，结合专家访谈、技术文献综述和交叉检验的情境分析，为策略决策提供支援。

本分析整合了结构化的一手和二手研究证据，并进行了严格的交叉检验，以确保结论的可靠性和有效性。一手研究包括对临床研究人员、放射性药物部门负责人、法规事务负责人和商业决策者的访谈，以收集有关试验设计、生产限制和支付方谈判的真实世界见解。二手研究纳入了同行评审的临床研究、监管指导文件、临床试验註册资讯以及放射化学和偶联方法的技术文献，以成熟的科学依据支持我们的发现。我们使用一个可复製的框架对这些资料来源进行三角验证，该框架整合了临床证据、操作可行性和商业性影响。

整合策略要务：临床创新、营运规划和相关人员协作如何整合，以推进PSMA标靶治疗的交付

PSMA抑制剂领域已发展成为一个复杂的生态系统，科学创新、生产能力、监管合规和支付方期望相互交织，共同决定临床影响和商业性成功。诊断影像和治疗方法的相互依存日益加深，为整合产品策略创造了机会，从而实现精准的患者选择和标靶治疗。同时，同位素采购、放射性药物分发能力和区域医疗保健系统结构等运作现实因素，对新型治疗方法如何以及何时惠及患者有显着影响。对于渴望在该领域占据领先地位的机构而言，基于严谨证据生成、供应链多元化和早期相关人员参与的清晰策略至关重要。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 前列腺特异性膜抗原抑制剂市场（依分子类型划分）

  • 单株抗体
    • 嵌合体体
    • 人性化
  • 低分子化合物
    • 磷酰胺
    • 基于尿素

9. 前列腺特异性膜抗原抑制剂市场依癌症分期划分

  • 晚期
  • 在地化
  • 转移性

10. 前列腺特异性膜抗原抑制剂市场依治疗线划分

  • 主要治疗
  • 二级治疗
  • 三级治疗

11. 前列腺特异性膜抗原抑制剂市场依给药途径划分

  • 静脉注射
  • 口服

12. 依患者年龄组别分類的前列腺特异性膜抗原抑制剂市场

  • 65至74岁
  • 75岁或以上
  • 65岁以下

13. 前列腺特异性膜抗原抑制剂市场（依应用划分）

  • 诊断影像检查
    • PET影像
    • SPECT影像
  • 治疗
    • 放射性配体疗法
      • 放射性卤化物络合物
      • 放射性金属共轭物
    • 小分子疗法

14. 前列腺特异性膜抗原抑制剂市场（依最终用户划分）

  • 癌症治疗中心
    • 私人的
    • 公共机构
  • 诊断检查室
  • 医院药房
  • 研究所

15. 前列腺特异性膜抗原抑制剂市场（按地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十六章 前列腺特异性膜抗原抑制剂市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

17. 各国前列腺特异性膜抗原抑制剂市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十八章美国前列腺特异性膜抗原抑制剂市场

19. 中国前列腺特异性膜抗原抑制剂市场

第20章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Blue Earth Diagnostics Ltd
  • Cardinal Health, Inc.
  • Curium US LLC
  • Eckert & Ziegler AG
  • ITM Isotope Technologies Munich SE
  • Lantheus Holdings, Inc.
  • Novartis AG
  • Pfizer Inc.
  • RayzeBio, Inc.
  • Siemens Healthineers AG
  • Telix Pharmaceuticals Limited
Product Code: MRR-AE420CB15314

The Prostate-Specific Membrane Antigen Inhibitor Market was valued at USD 687.32 million in 2025 and is projected to grow to USD 704.67 million in 2026, with a CAGR of 3.53%, reaching USD 876.32 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 687.32 million
Estimated Year [2026] USD 704.67 million
Forecast Year [2032] USD 876.32 million
CAGR (%) 3.53%

A rigorous overview of the scientific rationale, clinical imperatives, and operational complexities defining contemporary PSMA inhibitor development and deployment

Prostate-specific membrane antigen (PSMA) inhibitors have emerged as pivotal agents at the intersection of diagnostic imaging and targeted therapy for prostate malignancies. These agents exploit the overexpression of PSMA on prostate cancer cells to enable precise tumor visualization and to deliver cytotoxic payloads selectively, thereby creating a unified theranostic framework that aligns diagnostics with therapeutic intent. The clinical trajectory of PSMA inhibitors spans early detection through advanced disease management, and the modality's adaptability across imaging platforms and radioligand conjugates has catalyzed renewed interest among clinicians, regulators, and investors.

Against this backdrop, stakeholders face complex trade-offs involving clinical efficacy, manufacturing complexity, regulatory rigor, and payer acceptance. Diagnostic applications require high specificity and reproducibility across PET and SPECT imaging protocols, while therapeutic applications demand scalable radiochemistry, cold-chain logistics, and robust safety monitoring. The development lifecycle for PSMA-targeted agents also intersects with evolving standards for companion diagnostics and biomarker-driven trial designs, which in turn shape clinical adoption. As a result, strategic decisions made today about modality selection, manufacturing partnerships, and clinical positioning will determine the competitive landscape for years to come. This report synthesizes the scientific advances and commercial realities that inform those decisions, offering a rigorous synthesis of the technical, clinical, and operational dimensions that define the PSMA inhibitor domain.

How converging innovations in radiochemistry, theranostics, regulatory clarity, and supply chain models are reshaping competitive positioning for PSMA inhibitors

Recent years have seen transformative shifts across scientific innovation, regulatory pathways, and commercial expectations that together are redefining the PSMA inhibitor landscape. Advances in radiochemistry and conjugation approaches have expanded the therapeutic armamentarium from monoclonal antibody constructs to compact small molecules that enable faster tumor penetration and diversified administration routes. Concurrently, the maturation of theranostic paradigms means that diagnostic imaging is no longer a downstream activity but an integral component of patient selection, response assessment, and adaptive treatment planning, which has both clinical and reimbursement implications.

Regulatory frameworks have adapted to accommodate these hybrid products, emphasizing evidence generation for safety and efficacy while expecting manufacturers to demonstrate consistent production quality for radioligands and conjugates. Payer communities are increasingly focused on value-based outcomes, driving trials toward clinically meaningful endpoints beyond surrogate imaging metrics. In parallel, supply chain and manufacturing models have evolved: decentralized radiopharmacy networks and contract radiopharmaceutical manufacturers are scaling processes to meet localized demand while sponsors invest in scalable radiochemistry to mitigate isotope scarcity. These shifts interact dynamically; scientific advances enable new clinical uses, regulatory clarity promotes strategic investment, and commercial realities shape how therapies are priced and delivered at scale.

Assessing how changes in trade policy and tariff regimes can alter procurement economics, supply chain resilience, and regional manufacturing strategies for radiopharmaceuticals

Policy decisions that adjust tariffs and trade barriers can materially influence the economics of radiopharmaceutical development, manufacturing, and distribution. New or increased tariffs on clinical-grade isotopes, specialized precursors, or the equipment required for radiopharmaceutical production can raise input costs for manufacturers and contract service providers. These added costs reverberate through procurement channels, prompting re-evaluation of sourcing strategies, concentration of manufacturing in lower-cost jurisdictions, and hedging strategies for isotope supply. In turn, sponsors may accelerate investments in local radiochemistry infrastructure or pursue supply agreements that internalize production to reduce exposure to cross-border tariff risk.

Moreover, tariff-driven cost increases can slow the adoption curve in cost-sensitive care settings, particularly where reimbursement models remain constrained. Health systems and diagnostic laboratories may defer capital investments in cyclotrons, automated synthesis modules, or new imaging suites if operating margins are compressed. Conversely, the policy environment can incentivize nearshoring and strategic partnerships, which over time strengthen regional manufacturing ecosystems and create more resilient cold-chain logistics. Finally, tariffs influence collaboration patterns: multinational collaborations may be structured to minimize tariff liabilities, for example by transferring non-tariffable know-how or by localizing certain manufacturing steps. In sum, tariff changes act as a catalytic variable that shapes cost structures, supply chain architecture, and long-term industrial strategy for radiopharmaceutical stakeholders.

Comprehensive segmentation analysis revealing how application types, molecule classes, disease stage, treatment lines, care settings, routes, and age cohorts shape product strategies

A nuanced segmentation framework reveals where clinical, commercial, and operational priorities converge and diverge across applications, molecule classes, disease states, treatment lines, end users, administration routes, and patient demographics. Application-wise, the dual pathways of diagnostic imaging and therapeutic treatment each demand distinct capabilities: diagnostic imaging emphasizes high-resolution PET and SPECT compatibility and workflow integration with diagnostic laboratories and imaging centers, while therapeutic treatment requires radioligand or small molecule therapy expertise along with capacity for radiohalogen or radiometal conjugation and post-therapy safety monitoring. Regarding molecule type, monoclonal antibodies, whether chimeric or humanized, bring established protein-engineering and regulatory precedents, while small molecules such as phosphoramidate or urea-based agents offer manufacturing simplicity and favorable pharmacokinetics that support broader administration strategies.

Cancer stage and treatment line stratification further tailor clinical positioning: agents positioned for localized disease must demonstrate diagnostic precision and minimal off-target toxicity, while therapies for advanced or metastatic disease must show durable therapeutic benefit and manageable safety profiles across first-line through third-line and beyond settings. End users span cancer treatment centers, diagnostic laboratories, hospital pharmacies, and research institutes, with cancer treatment centers differentiated into private and public settings that vary in procurement practices and reimbursement arrangements. Administration route-intravenous versus oral-impacts patient experience, facility requirements, and outpatient management, while patient age groups such as those under 65, 65 to 74, and 75 and above influence trial design, comorbidity considerations, and real-world uptake. Together, these axes of segmentation define distinct product profiles, go-to-market strategies, and evidence requirements for stakeholders across the value chain.

Regional clinical and commercial dynamics that drive differentiated adoption pathways for PSMA diagnostics and therapeutics across the Americas, EMEA, and Asia-Pacific

Regional dynamics create differentiated clinical, regulatory, and commercial environments that influence how PSMA inhibitor programs are developed and deployed. In the Americas, advanced imaging infrastructure, established reimbursement mechanisms for novel diagnostics in many jurisdictions, and concentrated centers of clinical excellence enable rapid trial enrollment and early adoption of theranostic approaches; however, payer variability across public and private systems requires tailored pricing and evidence-generation strategies. In Europe, Middle East & Africa, regulatory heterogeneity and variable access to specialized radiopharmacy capacity mean that centralized manufacturing models often coexist with nascent local production, and stakeholders must navigate a mosaic of reimbursement policies and referral pathways that affect adoption timelines.

In the Asia-Pacific region, rapid investment in oncology infrastructure, coupled with large patient populations and expanding clinical trial activity, presents significant opportunities for scale. Government initiatives to strengthen local manufacturing capability and to expedite regulatory pathways for innovative therapies are notable, and partnerships with regional contract manufacturers and academic centers can accelerate clinical development. Across all regions, logistical considerations for isotope supply and cold-chain integrity are critical, and regional strategies that combine local production, cross-border collaboration, and capacity-building initiatives will determine how quickly new PSMA-targeted diagnostics and therapeutics move from clinical validation to routine clinical practice.

Competitive and collaborative industry behaviors emphasizing integrated ligand innovation, radiochemistry scale-up, and strategic partnerships to secure clinical and supply chain advantages

Organizational strategies across the competitive landscape reveal a focus on integrated capabilities that bridge discovery, radiochemistry scale-up, clinical validation, and commercial logistics. Innovative biotech firms are concentrating on optimizing ligand design, improving target affinity, and advancing small molecule constructs that facilitate both imaging and therapeutic conjugation. Established pharmaceutical companies are leveraging their regulatory expertise, manufacturing scale, and payer relationships to accelerate late-stage development and to negotiate supply agreements with health systems and group purchasing organizations. Meanwhile, specialized radiopharmaceutical manufacturers and contract development and manufacturing organizations are expanding capabilities for isotope handling, automated synthesis, and aseptic fill-finish to meet the unique requirements of radioligand therapies.

Strategic partnerships, licensing deals, and co-development arrangements are common mechanisms for addressing capability gaps. Collaborations between diagnostic developers and therapy sponsors enable linked companion diagnostic strategies that strengthen clinical adoption, while alliances with regional manufacturing partners mitigate logistical constraints and support local reimbursement engagement. Intellectual property strategies emphasize both core ligand chemistries and proprietary conjugation processes, and companies are also investing in production redundancies and quality systems to ensure continuity of supply. These convergent strategies indicate that successful competitors will combine scientific differentiation with operational excellence and pragmatic commercial partnerships.

Actionable recommendations for executives to align scientific innovation, supply chain resilience, regulatory engagement, and payer-focused evidence generation for PSMA programs

Industry leaders must adopt proactive strategies that align scientific development with supply chain resilience, regulatory engagement, and payer-centric evidence generation. First, prioritize platform flexibility by investing in ligand chemistries and conjugation techniques that can be adapted for both imaging and therapeutic use; platform versatility reduces time-to-market for new indications and enables more efficient use of clinical trial assets. Second, mitigate supply-side risk by diversifying isotope sources and by developing regional manufacturing partnerships that reduce dependency on single geographies; nearshoring and collaborative manufacturing agreements can secure clinical supply in volatile trade environments.

Third, engage early and continuously with regulators and payers to define acceptable clinical endpoints and real-world evidence pathways that reflect therapeutic value. Early alignment shortens approval timelines and reduces downstream reimbursement uncertainty. Fourth, pursue integrated commercialization models that couple diagnostic adoption with therapeutic rollout, ensuring that companion diagnostic access does not become a bottleneck for therapy uptake. Finally, invest in real-world data systems and patient-support services that demonstrate safety, adherence, and health-economic value in diverse care settings and across patient age cohorts. These recommendations together create a balanced approach that addresses scientific differentiation, commercial viability, and operational robustness.

A reproducible and transparent research methodology combining primary expert interviews, technical literature review, and cross-validated scenario analysis to support strategic decision-making

This analysis synthesizes evidence from structured primary research, secondary literature, and rigorous cross-validation to ensure the reliability and relevance of conclusions. Primary research included interviews with clinical investigators, radiopharmacy directors, regulatory affairs leaders, and commercial decision-makers to capture real-world insights into trial design, production constraints, and payer negotiations. Secondary research incorporated peer-reviewed clinical studies, regulatory guidance documents, trial registries, and technical literature on radiochemistry and conjugation methods to ground findings in established science. These data sources were triangulated using a reproducible framework that reconciles clinical evidence, operational feasibility, and commercial impact.

Quantitative and qualitative inputs were integrated through iterative analytic steps that included validation workshops with subject matter experts and sensitivity checks on operational assumptions. Where appropriate, findings were contextualized by comparing cross-regional regulatory timelines and supply chain configurations to identify structural drivers of adoption. Quality assurance processes included source attribution, expert peer review, and scenario testing to verify that conclusions remain robust under plausible variations in supply, regulatory, and reimbursement conditions. The methodology emphasizes transparency and reproducibility so that stakeholders can trace the evidentiary basis for key conclusions and adapt the approach to organization-specific risk tolerances and strategic priorities.

Synthesis of strategic imperatives showing how clinical innovation, operational planning, and stakeholder alignment converge to advance PSMA-targeted care delivery

The PSMA inhibitor domain has matured into a complex ecosystem where scientific innovation, manufacturing capabilities, regulatory alignment, and payer expectations intersect to determine clinical impact and commercial success. Diagnostic imaging and therapeutic modalities are increasingly interdependent, creating opportunities for integrated product strategies that deliver precision patient selection and targeted treatment. At the same time, operational realities such as isotope sourcing, radiopharmacy capacity, and the structure of regional healthcare systems materially influence how and when new therapies reach patients. Strategic clarity-rooted in rigorous evidence generation, supply chain diversification, and early stakeholder alignment-will be decisive for organizations seeking leadership in this space.

In closing, the most resilient and successful entrants will be those that combine technical differentiation with pragmatic operational planning and a clear value narrative for payers and clinicians. By aligning clinical strategy, manufacturing investment, and commercial execution, organizations can translate the promise of PSMA-targeted approaches into sustained improvements in patient outcomes and durable commercial performance. The insights in this report are designed to accelerate that alignment and to inform practical next steps for development teams, commercial leaders, and policy stakeholders.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Prostate-Specific Membrane Antigen Inhibitor Market, by Molecule Type

  • 8.1. Monoclonal Antibody
    • 8.1.1. Chimeric
    • 8.1.2. Humanized
  • 8.2. Small Molecule
    • 8.2.1. Phosphoramidate
    • 8.2.2. Urea-Based

9. Prostate-Specific Membrane Antigen Inhibitor Market, by Cancer Stage

  • 9.1. Advanced
  • 9.2. Localized
  • 9.3. Metastatic

10. Prostate-Specific Membrane Antigen Inhibitor Market, by Treatment Line

  • 10.1. First Line
  • 10.2. Second Line
  • 10.3. Third Line And Beyond

11. Prostate-Specific Membrane Antigen Inhibitor Market, by Administration Route

  • 11.1. Intravenous
  • 11.2. Oral

12. Prostate-Specific Membrane Antigen Inhibitor Market, by Patient Age Group

  • 12.1. 65 To 74
  • 12.2. 75 And Above
  • 12.3. Under 65

13. Prostate-Specific Membrane Antigen Inhibitor Market, by Application

  • 13.1. Diagnostic Imaging
    • 13.1.1. Pet Imaging
    • 13.1.2. Spect Imaging
  • 13.2. Therapeutic Treatment
    • 13.2.1. Radioligand Therapy
      • 13.2.1.1. Radiohalogen Conjugate
      • 13.2.1.2. Radiometal Conjugate
    • 13.2.2. Small Molecule Therapy

14. Prostate-Specific Membrane Antigen Inhibitor Market, by End User

  • 14.1. Cancer Treatment Centers
    • 14.1.1. Private
    • 14.1.2. Public
  • 14.2. Diagnostic Laboratories
  • 14.3. Hospital Pharmacies
  • 14.4. Research Institutes

15. Prostate-Specific Membrane Antigen Inhibitor Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Prostate-Specific Membrane Antigen Inhibitor Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Prostate-Specific Membrane Antigen Inhibitor Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. United States Prostate-Specific Membrane Antigen Inhibitor Market

19. China Prostate-Specific Membrane Antigen Inhibitor Market

20. Competitive Landscape

  • 20.1. Market Concentration Analysis, 2025
    • 20.1.1. Concentration Ratio (CR)
    • 20.1.2. Herfindahl Hirschman Index (HHI)
  • 20.2. Recent Developments & Impact Analysis, 2025
  • 20.3. Product Portfolio Analysis, 2025
  • 20.4. Benchmarking Analysis, 2025
  • 20.5. Blue Earth Diagnostics Ltd
  • 20.6. Cardinal Health, Inc.
  • 20.7. Curium US LLC
  • 20.8. Eckert & Ziegler AG
  • 20.9. ITM Isotope Technologies Munich SE
  • 20.10. Lantheus Holdings, Inc.
  • 20.11. Novartis AG
  • 20.12. Pfizer Inc.
  • 20.13. RayzeBio, Inc.
  • 20.14. Siemens Healthineers AG
  • 20.15. Telix Pharmaceuticals Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY CANCER STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY TREATMENT LINE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. UNITED STATES PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 15. CHINA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY CHIMERIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY CHIMERIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY CHIMERIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY HUMANIZED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY HUMANIZED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY HUMANIZED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY SMALL MOLECULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY SMALL MOLECULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY SMALL MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY PHOSPHORAMIDATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY PHOSPHORAMIDATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY PHOSPHORAMIDATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY UREA-BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY UREA-BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY UREA-BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY CANCER STAGE, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY ADVANCED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY ADVANCED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY ADVANCED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY LOCALIZED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY LOCALIZED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY LOCALIZED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY METASTATIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY METASTATIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY METASTATIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY THIRD LINE AND BEYOND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY THIRD LINE AND BEYOND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY THIRD LINE AND BEYOND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY 65 TO 74, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY 65 TO 74, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY 65 TO 74, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY 75 AND ABOVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY 75 AND ABOVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY 75 AND ABOVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY UNDER 65, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY UNDER 65, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY UNDER 65, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY DIAGNOSTIC IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY DIAGNOSTIC IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY DIAGNOSTIC IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY PET IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY PET IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY PET IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY SPECT IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY SPECT IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY SPECT IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY THERAPEUTIC TREATMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY THERAPEUTIC TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY THERAPEUTIC TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY THERAPEUTIC TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY RADIOLIGAND THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY RADIOLIGAND THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY RADIOLIGAND THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY RADIOLIGAND THERAPY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY RADIOHALOGEN CONJUGATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY RADIOHALOGEN CONJUGATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY RADIOHALOGEN CONJUGATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY RADIOMETAL CONJUGATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY RADIOMETAL CONJUGATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY RADIOMETAL CONJUGATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY SMALL MOLECULE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY SMALL MOLECULE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY SMALL MOLECULE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY CANCER TREATMENT CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY CANCER TREATMENT CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY CANCER TREATMENT CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY CANCER TREATMENT CENTERS, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY PRIVATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY PRIVATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY PRIVATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY PUBLIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY PUBLIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY PUBLIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY SMALL MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY CANCER STAGE, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. AMERICAS PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 118. AMERICAS PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 119. AMERICAS PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY THERAPEUTIC TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 120. AMERICAS PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY RADIOLIGAND THERAPY, 2018-2032 (USD MILLION)
  • TABLE 121. AMERICAS PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. AMERICAS PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY CANCER TREATMENT CENTERS, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY SMALL MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY CANCER STAGE, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY THERAPEUTIC TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY RADIOLIGAND THERAPY, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY CANCER TREATMENT CENTERS, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY SMALL MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY CANCER STAGE, 2018-2032 (USD MILLION)
  • TABLE 142. LATIN AMERICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY THERAPEUTIC TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY RADIOLIGAND THERAPY, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY CANCER TREATMENT CENTERS, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY SMALL MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY CANCER STAGE, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY THERAPEUTIC TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY RADIOLIGAND THERAPY, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY CANCER TREATMENT CENTERS, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY SMALL MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY CANCER STAGE, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY THERAPEUTIC TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY RADIOLIGAND THERAPY, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY CANCER TREATMENT CENTERS, 2018-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 180. MIDDLE EAST PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2032 (USD MILLION)
  • TABLE 182. MIDDLE EAST PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY SMALL MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY CANCER STAGE, 2018-2032 (USD MILLION)
  • TABLE 184. MIDDLE EAST PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 186. MIDDLE EAST PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 188. MIDDLE EAST PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY THERAPEUTIC TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 190. MIDDLE EAST PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY RADIOLIGAND THERAPY, 2018-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. MIDDLE EAST PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY CANCER TREATMENT CENTERS, 2018-2032 (USD MILLION)
  • TABLE 193. AFRICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 194. AFRICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. AFRICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2032 (USD MILLION)
  • TABLE 196. AFRICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY SMALL MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 197. AFRICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY CANCER STAGE, 2018-2032 (USD MILLION)
  • TABLE 198. AFRICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 199. AFRICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 200. AFRICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 201. AFRICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 202. AFRICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 203. AFRICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY THERAPEUTIC TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 204. AFRICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY RADIOLIGAND THERAPY, 2018-2032 (USD MILLION)
  • TABLE 205. AFRICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 206. AFRICA PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY CANCER TREATMENT CENTERS, 2018-2032 (USD MILLION)
  • TABLE 207. ASIA-PACIFIC PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. ASIA-PACIFIC PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. ASIA-PACIFIC PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2032 (USD MILLION)
  • TABLE 210. ASIA-PACIFIC PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY SMALL MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY CANCER STAGE, 2018-2032 (USD MILLION)
  • TABLE 212. ASIA-PACIFIC PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 215. ASIA-PACIFIC PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 216. ASIA-PACIFIC PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 217. ASIA-PACIFIC PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY THERAPEUTIC TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 218. ASIA-PACIFIC PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY RADIOLIGAND THERAPY, 2018-2032 (USD MILLION)
  • TABLE 219. ASIA-PACIFIC PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY CANCER TREATMENT CENTERS, 2018-2032 (USD MILLION)
  • TABLE 221. GLOBAL PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 222. ASEAN PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. ASEAN PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. ASEAN PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2032 (USD MILLION)
  • TABLE 225. ASEAN PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY SMALL MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 226. ASEAN PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY CANCER STAGE, 2018-2032 (USD MILLION)
  • TABLE 227. ASEAN PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 228. ASEAN PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 229. ASEAN PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 230. ASEAN PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 231. ASEAN PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 232. ASEAN PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY THERAPEUTIC TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 233. ASEAN PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY RADIOLIGAND THERAPY, 2018-2032 (USD MILLION)
  • TABLE 234. ASEAN PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 235. ASEAN PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY CANCER TREATMENT CENTERS, 2018-2032 (USD MILLION)
  • TABLE 236. GCC PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 237. GCC PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. GCC PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2032 (USD MILLION)
  • TABLE 239. GCC PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY SMALL MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 240. GCC PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY CANCER STAGE, 2018-2032 (USD MILLION)
  • TABLE 241. GCC PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 242. GCC PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 243. GCC PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 244. GCC PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 245. GCC PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 246. GCC PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY THERAPEUTIC TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 247. GCC PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY RADIOLIGAND THERAPY, 2018-2032 (USD MILLION)
  • TABLE 248. GCC PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 249. GCC PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY CANCER TREATMENT CENTERS, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPEAN UNION PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPEAN UNION PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPEAN UNION PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPEAN UNION PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY SMALL MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPEAN UNION PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY CANCER STAGE, 2018-2032 (USD MILLION)
  • TABLE 255. EUROPEAN UNION PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPEAN UNION PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPEAN UNION PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPEAN UNION PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPEAN UNION PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPEAN UNION PROSTATE-SPECIFIC MEMBRANE ANTIGEN INHIBITOR MARKET SIZE, BY THERAPEUTIC TREATMENT, 2018-20